Aspect Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Aspect Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.79K	Hold	5	–	–	﹤0.01%	452
2026 Q2	$3.12K	Sell	5 -17	-77%	-$11.6K	﹤0.01%	477
2026 Q1	$17K	Hold	22	–	–	0.01%	200
2025 Q4	$17K	Hold	22	–	–	0.01%	211
2025 Q3	$12.4K	Hold	22	–	–	0.01%	269
2025 Q2	$11.6K	Sell	22 -1	-4%	-$558	0.01%	265
2025 Q1	$14.6K	Hold	23	–	–	0.01%	225
2024 Q4	$16.4K	Hold	23	–	–	0.01%	226
2024 Q3	$24.2K	Hold	23	–	–	0.01%	171
2024 Q2	$24.2K	Hold	23	–	–	0.01%	167
2024 Q1	$22.1K	Hold	23	–	–	0.02%	170
2023 Q4	$20.2K	Buy	+23	New	+$18.9K	0.01%	173

Other funds holding REGN

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Vest Financial Mclean, Virginia $9.5B AUM 22.78% 1-Year Est. Return

GuoLine Advisory Singapore $1.16B AUM 31.35% 1-Year Est. Return

Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $10.8B AUM 9.05% 1-Year Est. Return

LMCG Investments Boston, Massachusetts $1.86B AUM 40.01% 1-Year Est. Return

Aspect Partners's REGN Position: Q3 2026 in Review

Aspect Partners held its Regeneron Pharmaceuticals (REGN) position steady in Q3 2026 at 5 shares worth $3.79K. The position accounts for ﹤0.01% of the portfolio, ranked #452.

Aspect Partners first reported a position in REGN in Q4 2023 and has held it in 12 quarters since. The position peaked at $24.2K in Q3 2024. 333 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

Aspect Partners held 5 shares of Regeneron Pharmaceuticals worth $3.79K as of Q3 2026.
Aspect Partners left its Regeneron Pharmaceuticals share count unchanged in Q3 2026.
Regeneron Pharmaceuticals made up ﹤0.01% of Aspect Partners's portfolio in Q3 2026, its #452 holding.
Aspect Partners first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 12 quarters since.
Aspect Partners's Regeneron Pharmaceuticals position peaked at $24.2K in Q3 2024.
333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Aspect Partners's 13F filing for Q3 2026, filed 20 Oct 2026.